Purpose: Sabatolimab (MBG453) and spartalizumab are monoclonal antibodies that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with advanced solid tumors. Experimental design: Primary objectives of the phase I/Ib part were to characterize the safety and estimate recommended doses for future studies (RP2Ds). Dose escalation was guided by a Bayesian (hierarchical) logistic regression model. Sabatolimab was administered intravenously, 20-1200 mg, every 2 or 4 weeks (Q2W, Q4W). Spartalizumab was administered intravenously, 80-400 mg, Q2W or Q4W. Results: Enrolled patients (n=219) had a range of cancers, most commonly ovarian (17%) and colorectal cancer (7%); patients received sabatolimab (n=133) or sabatolimab plus spartalizumab (n=86). The maximum tolerated dose was not reached. The most common adverse event suspected to be treatment-related was fatigue (9%, sabatolimab; 15%, combination). No responses were seen with sabatolimab. Five patients receiving combination treatment had partial responses (6%; lasting 12-27 months), in colorectal cancer (n=2), non-small cell lung cancer (NSCLC), malignant perianal melanoma, and SCLC. Of the five, two patients had elevated expression of immune markers in baseline biopsies; another three had >10% TIM-3 positive staining, including one patient with NSCLC who received prior PD-1 therapy. Conclusions: Sabatolimab plus spartalizumab was well tolerated and showed preliminary signs of antitumor activity. The RP2D for sabatolimab was selected as 800 mg Q4W (alternatively Q3W or Q2W schedules, based on modeling), with or without 400 mg spartalizumab Q4W.

Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors / G. Curigliano, H. Gelderblom, N. Mach, T. Doi, W.M. Tai, P.M. Forde, J. Sarantopoulos, P.L. Bedard, C. Lin, F.S. Hodi, S. Wilgenhof, A. Santoro, C. Sabatos-Peyton, T.A. Longmire, A. Xyrafas, H. Sun, S. Gutzwiller, L. Manenti, A. Naing. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 27:13(2021 Jul 01), pp. 3620-3629. [10.1158/1078-0432.CCR-20-4746]

Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors

G. Curigliano
Primo
Conceptualization
;
2021-07-01

Abstract

Purpose: Sabatolimab (MBG453) and spartalizumab are monoclonal antibodies that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with advanced solid tumors. Experimental design: Primary objectives of the phase I/Ib part were to characterize the safety and estimate recommended doses for future studies (RP2Ds). Dose escalation was guided by a Bayesian (hierarchical) logistic regression model. Sabatolimab was administered intravenously, 20-1200 mg, every 2 or 4 weeks (Q2W, Q4W). Spartalizumab was administered intravenously, 80-400 mg, Q2W or Q4W. Results: Enrolled patients (n=219) had a range of cancers, most commonly ovarian (17%) and colorectal cancer (7%); patients received sabatolimab (n=133) or sabatolimab plus spartalizumab (n=86). The maximum tolerated dose was not reached. The most common adverse event suspected to be treatment-related was fatigue (9%, sabatolimab; 15%, combination). No responses were seen with sabatolimab. Five patients receiving combination treatment had partial responses (6%; lasting 12-27 months), in colorectal cancer (n=2), non-small cell lung cancer (NSCLC), malignant perianal melanoma, and SCLC. Of the five, two patients had elevated expression of immune markers in baseline biopsies; another three had >10% TIM-3 positive staining, including one patient with NSCLC who received prior PD-1 therapy. Conclusions: Sabatolimab plus spartalizumab was well tolerated and showed preliminary signs of antitumor activity. The RP2D for sabatolimab was selected as 800 mg Q4W (alternatively Q3W or Q2W schedules, based on modeling), with or without 400 mg spartalizumab Q4W.
Settore MED/06 - Oncologia Medica
21-apr-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
1078-0432.CCR-20-4746.full.pdf

embargo fino al 21/04/2022

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 759.63 kB
Formato Adobe PDF
759.63 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/839424
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 30
social impact